CSLLY News and Press, CSL Ltd ADR From 12/12/22

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics PR Newswire CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and othe...

CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment PR Newswire Long-term data from the pivotal HOPE-B study show a on...

Summary Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49. The Hemophilia B treatment market is complex and in need of a remedial breakthrough, forming part of our buy thesis. Rate buy. ...

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B PR Newswire -  This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or elimina...

Summary CSL Limited's recent R&D investor briefing suggests that the company has been able to build a strong R&D pipeline without overspending. Separately, CSL Limited expects the top line of its recently acquired pharmaceuticals company to generate a reasonably good reven...

Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022 Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips A strategic collaboration has today’s traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a w...

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology PR Newswire KING OF PRUSSIA, Pa. , Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has ...

CSL Plasma Expands in California with New Donation Centers to Collect Life-Saving Plasma PR Newswire New Centers in Stockton and Hayward join other CSL Plasma locations in California to help meet growing demand for medicines derived from plasma BOCA R...

CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine PR Newswire CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. ...